Related Experiment Video
Updated: Aug 7, 2025
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Synthesis, characterization, molecular docking studies of Mn(II)Prolinedithiocarbamate and its potential as
Sulistiani Jarre1, Indah Raya2, Prihantono3
1Department of Chemistry, Faculty of Mathematics, and Natural Science, Hasanuddin University Makassar, Makassar, Indonesia, 90245.
Abstract:
Breast cancer is a non-communicable disease but dangerous for women, and research on anti-breast cancer drug compounds is being investigated. Mn(II)Prolinedithiocarbamate (MnProDtc) complex was synthesized and characterized in cytotoxicity and in silico assay by molecular docking. Dithiocarbamate ligand plays an important role as an anticancer agent. Melting point determination, conductivity, UV-Vis spectroscopy, FT-IR spectroscopy, XRD, and HOMO-LUMO have been studied. The binding of MnProDtc to cancer cells was examined by molecular docking, showing that the active sites of the MCF-7 strain, namely the protein O(6)-methylguanine-DNA methyltransferase (MGMT), caspase-8, and the estrogen receptor, bind to the complex. The results of the cytotoxic test of MCF-7 cancer cells undergoing apoptosis at a concentration of 37.50 μg/ml with an IC50 value of 453.96 μg/ml showed moderate anticancer activity in MCF-7 cancer cells.
Insights
Researchers explored Mn(II)Prolinedithiocarbamate (MnProDtc) as a potential breast cancer treatment. Molecular docking and cytotoxicity tests showed MnProDtc exhibits moderate anticancer activity against MCF-7 cells by targeting key proteins.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Materials Science
Background:
- Breast cancer remains a significant global health challenge for women.
- Research into novel anti-breast cancer drug compounds is crucial for effective treatment.
- Dithiocarbamate ligands are recognized for their potential anticancer properties.
Purpose of the Study:
- To synthesize and characterize Mn(II)Prolinedithiocarbamate (MnProDtc) complex.
- To evaluate the in silico and in vitro anticancer activity of MnProDtc against breast cancer cells.
- To investigate the molecular interactions of MnProDtc with key cancer-related proteins.
Main Methods:
- Synthesis and characterization of MnProDtc using techniques like melting point, conductivity, UV-Vis, FT-IR, and XRD.
- In silico molecular docking studies to predict binding interactions with target proteins.
- Cytotoxicity assays on MCF-7 breast cancer cells to determine IC50 values and assess apoptosis induction.
Main Results:
- MnProDtc was successfully synthesized and characterized.
- Molecular docking revealed binding of MnProDtc to critical sites in MCF-7 cells, including MGMT, caspase-8, and estrogen receptor.
- Cytotoxicity tests demonstrated moderate anticancer activity against MCF-7 cells, with apoptosis observed at 37.50 μg/ml and an IC50 of 453.96 μg/ml.
Conclusions:
- Mn(II)Prolinedithiocarbamate (MnProDtc) shows promise as a potential therapeutic agent for breast cancer.
- The observed anticancer effects are likely mediated through interactions with key cellular targets involved in cancer progression and survival.
- Further research is warranted to optimize MnProDtc for clinical application in breast cancer treatment.
